Fluticasone propionate/formoterol for COPD management: a randomized controlled trial
A Papi, D Dokic, W Tzimas, I Mészáros… - … journal of chronic …, 2017 - Taylor & Francis
Purpose To evaluate fluticasone propionate/formoterol (FP/FORM) in COPD. Patients and
methods COPD patients with forced expiratory volume in 1 s (FEV1)≤ 50% predicted and≥ …
methods COPD patients with forced expiratory volume in 1 s (FEV1)≤ 50% predicted and≥ …
The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD
A Papi, PW Jones, PS Dalvi, K McAulay… - … Journal of Chronic …, 2015 - Taylor & Francis
Inhaled corticosteroid/long-acting β2-agonist combination therapy is recommended in
chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The …
chronic obstructive pulmonary disease (COPD) patients at high risk of exacerbations. The …
Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes
A Anzueto, GT Ferguson, G Feldman… - COPD: Journal of …, 2009 - Taylor & Francis
Prevention and treatment of COPD exacerbations are recognized as key goals in disease
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
management. This randomized, double-blind, parallel-group, multicenter study evaluated …
A short-term comparison of fluticasone propionate/salmeterol with ipratropium bromide/albuterol for the treatment of COPD
JF Donohue, C Kalberg, A Emmett, K Merchant… - … in Respiratory Medicine, 2004 - Springer
Background: This is the first comparison of two combination therapies, fluticasone
propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of …
propionate/salmeterol and ipratropium bromide/albuterol (salbutamol), for the treatment of …
Controlled trial of inhaled fluticasone propionate in moderate to severe COPD
WH Thompson, P Carvalho, JP Souza, NB Charan - Lung, 2002 - Springer
Inhaled corticosteroids are often used in the treatment of stable chronic obstructive
pulmonary disease (COPD), however, studies of these agents have had mixed results …
pulmonary disease (COPD), however, studies of these agents have had mixed results …
[HTML][HTML] Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD
AB Tonnel, I Tillie-Leblond, V Attali, Z Bavelele… - Respiratory …, 2011 - Elsevier
BACKGROUND: The predictive factors for treatment response in patients with severe
chronic obstructive pulmonary disease (COPD) are unknown. We investigated predictive …
chronic obstructive pulmonary disease (COPD) are unknown. We investigated predictive …
[HTML][HTML] Efficacy and safety of once-daily fluticasone furoate/vilanterol (100/25 mcg) versus twice-daily fluticasone propionate/salmeterol (250/50 mcg) in COPD …
MT Dransfield, G Feldman, P Korenblat, CF LaForce… - Respiratory …, 2014 - Elsevier
Background Fluticasone furoate/vilanterol (FF/VI) is an inhaled corticosteroid/long-acting
beta 2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD …
beta 2-agonist (ICS/LABA), recently approved as once-daily maintenance therapy for COPD …
Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD–mixed treatment comparisons of clinical efficacy
G Stynes, H Svedsater, J Wex, S Lettis, D Leather… - Respiratory …, 2015 - Springer
Background Fluticasone furoate (FF)/vilanterol (VI) 100/25 mcg is a once-daily inhaled
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …
corticosteroid (ICS)/long-acting beta 2 agonist (LABA) treatment approved in the United …
Cost–effectiveness of fluticasone propionate in the treatment of chronic obstructive pulmonary disease: a double-blind randomized, placebo-controlled trial
JG Ayres, MJ Price, J Efthimiou - Respiratory medicine, 2003 - Elsevier
Background: Chronic obstructive pulmonary disease (COPD) is a debilitating disease and
places a large financial burden on health-care systems and society. We prospectively …
places a large financial burden on health-care systems and society. We prospectively …
Fluticasone propionate/salmeterol 250/50 μg versus salmeterol 50 μg after chronic obstructive pulmonary disease exacerbation
JA Ohar, GD Crater, A Emmett, TJ Ferro, AN Morris… - Respiratory …, 2014 - Springer
Background Inhaled long-acting beta 2 agonists used alone and in combination with an
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD …
inhaled corticosteroid reduce the risk of exacerbations in patients with stable COPD …